Meliton AY, Meng F, Tian Y, Sarich N, Mutlu GM, Birukova AA, Birukov KG. Oxidized phospholipids protect against lung injury and endothelial barrier dysfunction caused by heat-inactivated Staphylococcus aureus.
We explored the more general protective effects of OxPAPC and investigated whether delayed posttreatment with OxPAPC boosts the recovery of lung inflammatory injury and EC barrier dysfunction triggered by intratracheal injection of heat-killed gram-positive Staphylococcus aureus (HKSA) bacteria. HKSA-induced pulmonary EC permeability, activation of p38 MAP kinase and NF-B inflammatory cascades, secretion of IL-8 and soluble ICAM1, fibronectin deposition, and expression of adhesion molecules ICAM1 and VCAM1 by activated EC were significantly attenuated by cotreatment as well as posttreatment with OxPAPC up to 16 h after HKSA addition. Remarkably, posttreatment with OxPAPC up to 24 h post-HKSA challenge dramatically accelerated lung recovery by restoring lung barrier properties monitored by Evans blue extravasation and protein content in bronchoalveolar lavage (BAL) fluid and reducing inflammation reflected by decreased MIP-1, KC, TNF-␣, IL-13 levels and neutrophil count in BAL samples. These studies demonstrate potent in vivo and in vitro protective effects of posttreatment with anti-inflammatory oxidized phospholipids in the model of ALI caused by HKSA. These results warrant further investigations into the potential use of Ox-PAPC compounds combined with antibiotic therapies as a treatment of sepsis and ALI induced by gram-positive bacterial pathogens. oxidized phospholipids; cytoskeleton; pulmonary endothelium; inflammation; vascular leak SEPSIS IS THE 10th leading cause of death in the United States (33) and bacterial inflammation is a major contributor to the development of acute respiratory distress syndrome (ARDS). About 50% of all cases of sepsis are caused by gram-positive bacteria (38) . In pneumonia caused by Staphylococcus aureus, the intense inflammatory response that is triggered by this infection can lead to rapid development of lung injury and ARDS (23, 28) . Although antibiotics are used to ameliorate bacterial dissemination, even inactivated or killed bacteria continue acting as a "danger signal" and activate an inflammatory response often leading to a cytokine storm and severe lung injury.
Gram-positive bacterial pathogens stimulate inflammatory responses via the activation of Toll-like receptors (TLRs) (26, 45) , leading to acute pulmonary inflammation characterized by the influx of neutrophils and increased cytokine levels in lung parenchyma and bronchoalveolar lavage (BAL) fluid (29) . TLR2 is considered a major receptor involved in the host defense against gram-positive bacteria, although it also recognizes lipoproteins from other bacterial species, and other TLRs cooperate with TLR2 in activation of an inflammatory signaling (35, 41) .
TLR-induced inflammatory events in endothelial cells are mediated by phosphorylation/activation of mitogen-activated protein kinases (MAPK) p42/p44, JNK1/2, p38, and the nuclear factor-B (NF-B) pathway (1) . As a result, TLR2-induced activation of inflammatory signaling promotes the transient elevation of monocyte chemoattractant protein-1 (MCP-1), interleukin-8 (IL-8), macrophage inflammatory protein-1␣ (MIP-1␣), MIP-1␤, IL-6, and tumor necrosis factor-␣ (TNF-␣) in vivo and in vitro (30, 48) and also leads to the activation and recruitment of neutrophils and macrophages into the lungs (48) .
Previous studies have described potent barrier-protective effects of specific products of 1-palmitoyl-2-arachidonoyl-snglycero-3-phosphorylcholine oxidation (OxPAPC) (3, 13) on the vascular endothelium and demonstrated a key role of Rac1 and Rap1 GTPases in OxPAPC-induced endothelial cell (EC) barrier enhancement (3, 6, 9, 17) . Because of direct barrier enhancing effects on lung endothelial monolayers, OxPAPC is capable of suppressing the lung vascular leak induced by edemagenic and inflammatory molecules (thrombin, LPS) (8, 37) or excessive lung distension during mechanical ventilation (36) . Concurrent administration of OxPAPC has been also shown to antagonize interaction of TLR4 and TLR9 ligands, LPS, and CpG DNA with their cognate receptors. As a result, OxPAPC inhibited activation of MAPK and NF-B signaling and inflammatory lung injury (18, 31, 37 ). The present model of OxPAPC anti-inflammatory effects assumes competitive interaction of OxPAPC with TLR receptors, which prevents receptor interaction with proinflammatory ligands, i.e., LPS. However, effects of OxPAPC posttreatment on modulation of ongoing inflammation and stimulation of organ recovery after initiation of inflammation remain to be explored.
This study investigated the protective effects of OxPAPC against lung inflammation and EC barrier dysfunction caused by gram-positive pathogens, the heat-killed S. aureus particles (HKSA). This study used pulmonary EC culture and a mouse model of HKSA-induced lung injury to test therapeutic effects of OxPAPC posttreatment (2-24 h) on modulation of HKSAinduced pulmonary EC barrier dysfunction and inflammation in vitro and parameters of lung injury in vivo. We evaluated anti-inflammatory and barrier-protective effects of OxPAPC posttreatment as a potential therapeutic strategy to mitigate lung injury and promote recovery in the model of lung injury caused by gram-positive pathogens.
MATERIALS AND METHODS
Cell culture and reagents. Human pulmonary artery endothelial cells (HPAEC) were obtained from Lonza (Allendale, NJ). Cells were maintained in a complete culture medium according to the manufacturer's recommendations and used for experiments at passages 5-8. Phospho-p38, IB␣, and p65-NF-B and phosphoS 536 -p65-NF-B antibodies were obtained from Cell Signaling (Beverly, MA); VEcadherin, fibronectin, ICAM1, and VCAM1 from Santa Cruz Biotechnology (Santa Cruz, CA). HKSA was obtained from InvivoGen (San Diego, CA). Nonoxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC) and dimirystoyl-sn-glycero-3-phosphorylcholine (DMPC) were obtained from Avanti Polar Lipids (Alabaster, AL). OxPAPC was obtained by exposure of dry lipid to air as previously (3, 46) . The extent of oxidation was measured by positive ion electrospray mass spectrometry (ESI-MS) described elsewhere (46) . OxPAPC dissolved in chloroform was stored at Ϫ70°C and used within 2 wk after mass spectrometry testing. Reagents for immunofluorescence were purchased from Molecular Probes (Eugene, OR). Unless specified, biochemical reagents were obtained from Sigma (St. Louis, MO).
Assessment of endothelial permeability. The cellular barrier properties were analyzed by measurements of transendothelial electrical resistance (TER) across confluent human pulmonary artery endothelial monolayers using an electrical cell-substrate impedance sensing system (Applied Biophysics, Troy, NY) as previously described (5, 7) . Express micromolecule permeability testing assay (XPerT) was recently developed by our group (21) and currently available from Millipore (Vascular Permeability Imaging Assay, catalog no. ). This assay is based on the high-affinity binding of avidinconjugated FITC-labeled tracer to the biotinylated extracellular matrix proteins immobilized on the bottom of culture dishes after the EC barrier is compromised by treatment with a barrier-disruptive agonist. XPerT permeability assays were performed in 96-well plates. Visualization of EC monolayer permeability was performed in HPAEC plated on glass coverslips coated with biotinylated gelatin followed by agonist stimulation, incubation with FITC-avidin tracer, fluorescence microscopy, and imaging analysis as previously described (21, 42) .
Fractionation and immunoblotting. Confluent HPAEC were stimulated with HKSA and the nuclear fraction was isolated using the S-PEK kit (EMD Chemicals, Gibbstown, NJ). Immunoblotting detection of proteins of interest was performed as described previously (3) . Protein extracts from mouse lungs or EC were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes, and the membranes were incubated with specific antibodies of interest. Immunoreactive proteins were detected with the enhanced chemiluminescence detection system according to the manufacturer's protocol (Amersham, Little Chalfont, UK).
Immunofluorescence. Endothelial monolayers plated on glass coverslips were subjected to immunofluorescence staining with the appropriate antibody, as described previously (11) . Texas red phalloidin was used to visualize F-actin. After immunostaining, slides were analyzed with a Nikon video imaging system (Nikon Instech, Tokyo, Japan). Images were processed with Image J software (National Institutes of Health, Bethesda, MD) and Adobe Photoshop 7.0 (Adobe Systems, San Jose, CA) software (11) . Quantitative analysis of VEcadherin-positive adherens junctions was performed by measurements of junctional VE-cadherin immunoreactivity normalized to square area in control and stimulated cells as previously reported (15) . Quantitative analysis of paracellular gap formation and F-actin cytoskeleton was performed as previously described (4, 7, 12) . At least 20 microscopic fields for each experimental condition were analyzed. The 16-bit images were analyzed by use of MetaVue 4.6 software (Universal Imaging, Downington, PA). Paracellular gaps were manually marked out, and images were differentially segmented between gaps and cells based on image grayscale levels. The gap formation was expressed as a ratio of the gap area to the area of the whole image. The values were statistically processed by use of Sigma Plot 7.1 (SPSS Science, Chicago, IL) software. For analysis of stress fiber formation, F-actin immunoreactivity were captured based on image grayscale levels, and immunofluorescence signal intensity was measured and expressed in arbitrary units per microscopic field. The values were statistically processed with Sigma Plot 7.1 (SPSS Science, Chicago, IL) software.
Cytokine analysis. The concentrations of KC, MIP-1, TNF-␣, and IL-13 in mouse BAL fluid samples were measured by using a Mouse Cytokine Multiplex Panel according to the manufacturer's protocol (Millipore, Billerica, MA). For IL-8 and soluble ICAM1 (sICAM1) measurements in preconditioned medium of human pulmonary EC cultures, supernatants from treated EC were collected and centrifuged to remove debris. IL-8 and sICAM1 levels were determined by ELISA (R&D Systems, Minneapolis, MN) following the manufacturer's protocol.
In vivo model of acute lung injury. All animal care and treatment procedures were approved by the University of Chicago Institutional Animal Care and Use Committee and were handled according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Adult male C57BL/6J mice, 8 -10 wk old, with an average weight 20 -25 g (Jackson Laboratories, Bar Harbor, ME) were anesthetized with an intraperitoneal injection of ketamine (75 mg/kg) and acepromazine (1.5 mg/kg). HKSA (2 ϫ 10 8 bacterial cells/mouse) or sterile saline solution was injected intratracheally in a small volume (20 -30 l) using a 20-gauge catheter (Penn-Century, Philadelphia, PA). Five hours after intratracheal HKSA instillation, OxPAPC (1.5 mg/kg), DMPC (1.5 mg/kg), or sterile saline solution was administrated by retro-orbital injection or intravenous injection in the external jugular vein. At 24 h, animals were euthanized by exsanguination under anesthesia. Measurements of cell count and protein concentration in BAL and determination of myeloperoxidase activity in lung tissue homogenates were performed as previously described (8, 22) . Evans blue dye (30 ml/kg) was injected into the external jugular vein 2 h before termination of ventilation to assess vascular leak as described previously (34, 36) . Histological assessment of lung injury was performed as descried elsewhere (22, 36) .
Statistical analysis. Results are expressed as means Ϯ SD of three to six independent experiments. Stimulated samples were compared with controls by unpaired Student's t-test. For multiple-group comparisons, a one-way ANOVA, followed by the post hoc Tukey test, were used. P Ͻ 0.05 was considered statistically significant.
RESULTS

HKSA induces barrier disruption in pulmonary endothelium.
Dose-dependent (1-10 ϫ 10 8 bacterial cells/ml) effects of HKSA on pulmonary EC permeability were assessed by measuring TER. All HKSA concentrations significantly reduced TER within 4 -5 h, which remained decreased up to 20 h following treatment (Fig. 1A) .
The effect of HKSA on lung EC monolayer permeability associated with septic inflammation was further analyzed with an express assay testing EC monolayer permeability for macromolecules, which was described in our recent study (21) . In agreement with TER measurements, HKSA gradually increased EC monolayer permeability for FITC-labeled avidin http://ajplung.physiology.org/ during a 2-to 24-h period (Fig. 1B) . Analysis of cytoskeletal remodeling in HKSA-challenged cells showed the disappearance of the cortical F-actin rim and formation of actin stress fibers and paracellular gaps, which reflect compromised EC monolayer integrity (Fig. 1C) .
HKSA induces inflammatory activation of pulmonary endothelium. Activation of intracellular signaling by HKSA was evaluated by the analysis of phosphorylation/activation status of signaling proteins involved in the stress response and inflammatory cascades. HKSA induced rapid time-dependent phosphorylation of stress-activated p38 MAP kinase. Activation of inflammatory signaling stimulates IB␣ phosphorylation by IB kinase, subsequent degradation by the proteasome and IB␣ degradation leading to NF-B release and translocation to the nucleus, where it triggers the transcription of proinflammatory cytokines, such as TNF-␣, IL-1␤, IL-6, and IL-8 (20) . HKSA caused increased phosphorylation of p38 stress MAP kinase and degradation of IB␣, an inhibitory subunit of the NF-B complex ( Fig. 2A) , resulting in the activation of NF-B-dependent transcription.
The nuclear fractionation assay showed HKSA-induced phosphorylation of NF-B p65-subunit at Ser 536 and its translocation to the nuclear fraction (Fig. 2B ). HKSA-induced nuclear localization of p65-NF-B was further confirmed by immunofluorescence staining of control and HKSA-stimulated EC with NF-B antibody (Fig. 2C) .
Activation of inflammatory signaling led to increased expression of adhesion molecules ICAM1 and VCAM1 and increased EC production of fibronectin, the extracellular matrix protein involved in the propagation of the inflammatory response, which was observed at 4 -48 h after HKSA challenge (Fig. 2D) .
OxPAPC protects against HKSA-induced endothelial monolayer disruption. Previously described barrier-protective effects of OxPAPC against EC barrier disruption caused by gram-negative pathogen LPS were mediated at least in part by direct inhibition of TLR4 receptor. Effects of OxPAPC in the model of Staphylococcus aureus-induced EC barrier dysfunction remained unclear and were investigated in the present study.
Effects of OxPAPC on EC permeability induced by HKSA were examined using the XPerT permeability assay described in METHODS. Quantitative analysis was first performed in 96-well plates with EC monolayers and the measurement of matrix-bound FITC-avidin fluorescence using a microplate fluorimeter reader. In these experiments, HPAEC were cotreated with OxPAPC and HKSA for 6 h. Control experiments were performed with oxidation-resistant phospholipid DMPC as a negative control. OxPAPC, but not DMPC, dramatically attenuated disruptive effects of HKSA (Fig. 3A) .
Effects of OxPAPC on the EC cytoskeletal remodeling induced by HKSA were next examined by immunofluorescence staining and visualization of actin cytoskeleton and VE-cadherin-positive adherens junctions in pulmonary EC after 6 h of HKSA treatment, the time point corresponding to developed EC monolayer permeability increase. HKSA-induced formation of paracellular gaps (shown by arrows) and the disappearance of VE-cadherin from cell junctions in the lung EC, which reflects disruption of the EC monolayer integrity, was abolished by cotreatment with OxPAPC (Fig. 3B) .
OxPAPC suppresses inflammatory signaling activated by HKSA. Protective effects of OxPAPC on pulmonary EC barrier were further linked to OxPAPC-induced attenuation of inflammatory signaling pathways activated by HKSA. EC were cotreated with OxPAPC and HKSA for 1, 24, or 48 h. Control experiments were performed with nonoxidized PAPC or DMPC described above. Effects of OxPAPC on activation of stress and inflammatory signaling were evaluated by Western blot. OxPAPC attenuated HKSA-induced p38 MAPK phosphorylation and IB␣ subunit degradation after 2 h of HKSA treatment (Fig. 4A, top) , and suppressed expression of adhesion molecules ICAM1 and VCAM1 after 24 h (Fig. 4A, middle) . Of note, PAPC or DMPC administration failed to prevent EC inflammatory activation in response to HKSA. Increased cellular expression of ICAM1 by HKSA-stimulated EC was further confirmed by immunofluorescence staining of EC monolayers with an ICAM1 antibody (Fig. 4B) . We next analyzed deposition of fibronectin extracellular matrix by activated EC using immunofluorescent staining of coverslips with a fibronectin antibody after the cell detachment step. Increased fibronectin deposition by HKSA-stimulated pulmonary EC was observed after 48 h of HKSA treatment; this effect was abolished by cotreatment with OxPAPC (Fig. 4C) .
HKSA-induced EC inflammatory activation was additionally characterized by increased secretion of sICAM1 and IL-8 in cultured medium observed after 24 h of HKSA challenge. Cotreatment with OxPAPC abolished HKSA-induced sICAM1 and IL-8 production (Fig. 4D ). Control treatment with PAPC or DMPC was without effect.
OxPAPC posttreatment attenuates EC barrier dysfunction. Because treatment of ongoing inflammation with protective compounds represents a more clinically relevant scenario of pharmacological intervention, the following studies evaluated the effects of OxPAPC posttreatment on HKSA-induced EC monolayer barrier dysfunction in the in vitro assays. Permeability changes in pulmonary EC cultures treated with OxPAPC at various time points after HKSA challenge were monitored by the measurements of TER. OxPAPC was added 30 min, 2 h, 6 h, or 16 h after HKSA stimulation. Remarkably, at all time points including 16 h of HKSA posttreatment OxPAPC exhibited potent protective effect (Fig. 5A) .
Visualization of EC monolayer permeability for FITC-avidin tracer using the XPerT permeability assay showed robust HKSA-induced EC barrier dysfunction, which was almost completely blocked by OxPAPC posttreatment 6 h after HKSA challenge (Fig. 5B) . These effects were accompanied by disappearance of actin stress fibers and recovery of monolayer integrity in EC challenged with HKSA and posttreated with HKSA (Fig. 5C) .
Posttreatment with OxPAPC 30 min, 2 h, 6 h, and 16 h after HKSA challenge markedly attenuated ICAM1 and VCAM1 expression by pulmonary EC (Fig. 5C) . In complementary experiments, secretion of sICAM1 to the culture medium was measured at 0 min, 30 min, 2 h, 6 h, and 18 h of OxPAPC posttreatment after HKSA administration. OxPAPC suppressed sICAM1 production at all time points (Fig. 5D ). Control posttreatment with nonoxidized PAPC or DMPC did not exhibit protective effects.
HKSA induces lung injury in vivo. The time course of HKSA-induced lung injury was evaluated by the analysis of protein content and cell counts in the BAL samples taken from HKSA-challenged C57Bl/J6 mice. HKSA intratracheal administration caused prominent increases in both BAL cell counts (Fig. 6A ) and protein concentration (Fig. 6B) . The maximal effect was observed at day 2 after HKSA challenge, which was followed by a gradual decline and recovery by day 7. 2 time point of HKSA treatment was selected to evaluate the effects of OxPAPC posttreatment. The magnitude of changes in BAL protein and cell counts caused by HKSA was comparable to changes induced by LPS doses that were previously used in similar models of acute lung injury (ALI) (8) .
OxPAPC attenuates lung injury induced by HKSA in vivo. We performed intravenous administration of OxPAPC in these experiments using injection into the jugular vein or into the retro-orbital venous sinus 5 or 24 h after intratracheal HKSA administration. Control experiments were performed with DMPC, which was administered 5 h after HKSA instillation. OxPAPC posttreatment significantly reduced protein content (Fig. 6B) and total cell count (Fig. 6C) http://ajplung.physiology.org/ effect on HKSA-induced lung injury. Of note, both, intrajugular and retro-orbital routes of OxPAPC administration were equally efficient, suggesting future use of retro-orbital injection as a more convenient experimental manipulation.
Severity of lung injury and inflammation was further monitored by measurements of myeloperoxidase (MPO) activity, a marker of neutrophil activation and tissue oxidative stress. HKSA significantly increased MPO activity measured in tissue homogenates, whereas OxPAPC posttreatment was protective at both time points, 5 and 24 h, of HKSA instillation (Fig. 6D) .
Histological analysis of lung tissue sections stained with hematoxylin and eosin showed that the treatment with HKSA induced neutrophil infiltration in the lung parenchyma and caused appearance of areas with alveolar hemorrhage indicative of vascular disruption. In consistence with the BAL data, OxPAPC posttreatment 5 h after HKSA abolished these effects (Fig. 7A) .
Effects of OxPAPC posttreatment on the HKSA-induced lung vascular leak were evaluated by measurements of Evans blue extravasation into the lung tissue. Evans blue dye was intravenously injected 2 h before termination of the experiment. HKSA administration induced prominent Evans blue leakage from the vascular space into the lung parenchyma, which was suppressed by a single injection of OxPAPC after 5 h of HKSA (Fig. 7B) . Quantitative analysis of Evans bluelabeled albumin extravasation in the lung tissue confirmed these results. OxPAPC posttreatment attenuated HKSA-induced ICAM1 and VCAM1 expression in the lung, as detected by Western blot analysis of lung tissue homogenates (Fig. 7C) . DMPC had no protective effects.
Because HKSA treatment stimulated IL-8 production by human pulmonary EC cultures in vitro, effects of OxPAPC on HKSA-induced cytokine production were further tested in the murine model of ALI. The levels of mouse cytokines were measured in BAL samples by use of a multiplex cytokine ELISA assay. HKSA administration significantly increased KC, MIP-1, TNF-␣, and IL-13 levels detected in BAL samples (Fig. 7D) , whereas OxPAPC injection 5 h after HKSA significantly attenuated cytokine production. Altogether, these data demonstrate potent protective effects of OxPAPC posttreatment against lung inflammation and barrier dysfunction induced by gram-positive pathogens.
DISCUSSION
This study showed that HKSA-induced EC permeability and inflammation was abolished by posttreatment with OxPAPC. OxPAPC showed a strong anti-inflammatory effect and blunted HKSA-induced p38 MAP kinase, NF-B signaling, and inhibited HKSA-induced fibronectin deposition, IL-8 production, and release of soluble ICAM1 by pulmonary EC. Cotreatment of HKSA-challenged cells with OxPAPC prevented disruption of VE-cadherin-positive adherens junctions, formation of intercellular gaps, and cytoskeletal remodeling. The anti-inflammatory and barrier-protective activities were attributed to oxidized phospholipids, because treatments with nonoxidized PAPC or oxidation-resistant phospholipid, DMPC, did not affect HKSA-induced injury.
OxPAPC was also effective in the animal model of HKSAinduced lung injury. Of note, the utilization of separate routes of HKSA and OxPAPC administration in the in vivo studies allowed to avoid direct competitive inhibition of HKSA interaction with TLR receptors by OxPAPC. Concurrent intravenous administration of OxPAPC attenuated the HKSA-induced inflammatory and barrier-disruptive response, suggesting a major role of the pulmonary vascular endothelium in the pathogenesis of ALI caused by inhaled pathogens.
Many studies screening for novel protective compounds in cells and animal models of ALI utilize preventive or concurrent treatment protocols. Although the pretreatment approach remains valid for targeting of mechanisms preventing activation of injurious signaling and may still lead to identification of new protective molecules, mechanisms contributing to the suppression or reversal of the ongoing pathological process remain poorly understood. This study demonstrates for the first time that single intravenous injection of OxPAPC as posttreatment after HKSA challenge in the in vivo ALI model and in pulmonary EC culture significantly attenuated lung barrier dysfunction and acute inflammation. Unlike many other protective treatments, which become ineffective if applied later than 2-3 h after an inflammatory insult, OxPAPC posttreatment even after 16 -24 h of HKSA administration induced pronounced EC barrier recovery and improved lung function. OxPAPC posttreatment also reversed HKSA-induced induction of ICAM1 and VCAM1 expression by pulmonary EC, as well as HKSA-induced expression of adhesion molecules in the lung tissue and elevation of inflammatory cytokines KC, MIP-1, TNF-␣, and IL-13 in BAL samples. Of note, live bacteria may trigger additional inflammatory cascades and engage other cells types and cellular processes such as bacteria killing and phagocytosis. Thus further studies are required for the comprehensive evaluation of the beneficial effects of Ox-PAPC in the models of lung dysfunction caused by S. aureus.
Although the Rho pathway of vascular endothelial permeability is most common for endogenous vasoactive mediators (2, 19, 24, 40, 44, 47) , mechanisms of EC barrier dysfunction caused by bacterial pathogens and involvement of Rho signaling remain much less understood. A recent study showed that both Src and Rho were required for full NF-B activation caused by TLR2 ligands. Rho activation was reported downstream of TLR2-MyD88 (32). TLR2-dependent Rho activation was achieved via interaction with the Rho-specific GEF AKAP13 recruited by activated TLR2 (32) . Because Ox-PAPC inhibits agonist-induced Rho signaling via negative Rac-Rho GTPase cross talk (16, 36) , OxPAPC-dependent control of inflammatory signaling via negative regulation of Rho may be a plausible mechanism, which warrants further investigation.
The results of our present study strongly suggest a dual nature of OxPAPC protective effects toward lung barrier function: first, via blunting of Toll-like receptor/NF-B proinflammatory signaling cascade characterized in previous studies (18) , and second, via direct effects on cytoskeletal remodeling and enhancement of cell-cell interactions driven by Rac1-and Rap1-mediated mechanisms described by our group (10, 14, 17) . Appearance of oxidized phospholipids in inflamed and injured tissues (25, 27, 43) suggests an intriguing mechanism of self-regulation of tissue inflammation and recovery, whereby endogenous oxidized phospholipids may act as a negative feedback mechanism serving to attenuate the acute immune response to endotoxin, which involves activation of Toll-like receptors and also directly enhance lung vascular barrier properties. The efficacy of intravenous OxPAPC in attenuating ALI caused by intratracheal HKSA suggests a possible therapeutic role for this group of compounds. Moreover, the recent identification of specific oxidized phospholipid species exhibiting potent barrier-protective properties along with anti-inflammatory effects (13, 39) strongly supports the clinical significance of oxidized phospholipids as a potential new group of therapeutic agents. Further research toward development of stable synthetic molecules recapitulating biological activities of protective OxPAPC compounds will be important to more precisely characterize specific mechanisms of action of OxPAPC in vivo and increase their stability. Future studies in this direction may uncover a new treatment strategy utilizing Ox-PAPC as dual-function compounds with anti-inflammatory and barrier-protective properties for treatment of various conditions leading to ALI and/or sepsis.
GRANTS
This research was supported by National Heart, Lung, and Blood Institute Grants HL87823 and HL076259 for K. G. Birukov and HL089257 and HL107920 for A. A. Birukova.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s). 
AUTHOR CONTRIBUTIONS
